“A junior doctor I spoke to the other day was talking about what a difficult time she’d found in another hospital,” says Dorothy Wade, a psychologist at University College Hospital in London. “And I said, ‘Didn’t you have anything like this at the other hospital?’ And she said, ‘No, absolutely nothing. There was nothing on… Read More »
UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »
At a time when germs are growing more resistant to common antibiotics, many companies that are developing new versions of the drugs are hemorrhaging money and going out of business, gravely undermining efforts to contain the spread of deadly, drug-resistant bacteria. Antibiotic start-ups like Achaogen and Aradigm have gone belly up in recent months, pharmaceutical… Read More »